3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA

BMC Neuroscience

Table 1 Concentration of l-DOPA, dopamine and their metabolites in striatal astrocytes 4 h after methyl-l-DOPA (100 µM) and/or 3-OMD (10 µM) exposure

	Control	3-OMD	Methyl-l-DOPA	3-OMD + methyl-l-DOPA
l-DOPA	N.D.	N.D.	411.0 ± 12.1**	347.0 ± 15.6**^, ^##
DA	N.D.	N.D.	N.D.	N.D.
DOPAC	N.D.	N.D.	N.D.	N.D.
HVA	N.D.	N.D.	N.D.	N.D.
3-OMD	N.D.	12.5 ± 1.02**	15.3 ± 1.57**	26.0 ± 0.83**^, ^## ^, ^$$

Striatal astrocytes were treated with methyl-l-DOPA (100 µM) and/or 3-OMD (10 µM) for 4 h. The concentrations of l-DOPA, DA, DOPAC, HVA and 3-OMD were measured by HPLC assay. N.D: not detected. Data (pmol/mg protein) are presented as mean ± SEM (n = 4)
* p < 0.05, ** p < 0.001 versus control group
^## p < 0.001 versus methyl-l-DOPA-treated group
^$$p < 0.001 versus 3-OMD-treated group

ISSN: 1471-2202